MEI Pharma Revenue and Competitors
Estimated Revenue & Valuation
- MEI Pharma's estimated annual revenue is currently $33.3M per year.
- MEI Pharma's estimated revenue per employee is $220,695
- MEI Pharma's total funding is $160.4M.
Employee Data
- MEI Pharma has 151 Employees.
- MEI Pharma grew their employee count by -21% last year.
MEI Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Information Technology | Reveal Email/Phone |
2 | VP, Drug Safety & Pharmacovigilance | Reveal Email/Phone |
3 | SVP, Regulatory Affairs | Reveal Email/Phone |
4 | VP, Clinical Operations | Reveal Email/Phone |
5 | SVP, Corporate Affairs | Reveal Email/Phone |
6 | VP, Technical Operations | Reveal Email/Phone |
7 | VP, Regulatory Affairs | Reveal Email/Phone |
8 | VP, Program And Alliance Management | Reveal Email/Phone |
9 | SVP, Clinical Development | Reveal Email/Phone |
10 | VP Clinical Operations | Reveal Email/Phone |
MEI Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is MEI Pharma?
MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor that has been granted Breakthrough Therapy Designation from the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ?75 years of age or unfit for intensive chemotherapy. Our pipeline of drug candidates also includes ME-401 (formerly PWT143), a next-generation oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor. For more, please go to www.meipharma.com.
keywords:N/A
$160.4M
Total Funding
151
Number of Employees
$33.3M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MEI Pharma News
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's...
Daniel P. Gold, president and chief executive officer of MEI Pharma, noted that the regulatory agency's position on the benefit of risk with...
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's...
SAN DIEGO, Sept. 3, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 132,000 shares of the company's common stock to four new employ ...
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Brian Drazba, chief financial officer of MEI Pharma, has informed the company that he is retiring. Mr. Drazba, an ind ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $48.2M | 151 | 6% | N/A |
#2 | $30.4M | 151 | 26% | N/A |
#3 | $34.1M | 151 | 8% | N/A |
#4 | $33.9M | 151 | N/A | N/A |
#5 | $24.1M | 151 | N/A | N/A |